Acticor Biotech

OverviewSuggest Edit

Acticor Biotech is a biopharmaceutical company developing an antithrombotic agent for the treatment of the acute phase of ischemic stroke. The Company develops a biologic drug candidate based on academic research on a platelet glycoprotein called GPVI.

HQParis, FR

Latest Updates

Employees (est.) (Oct 2020)18
Cybersecurity ratingAMore

Key People/Management at Acticor Biotech

Gilles Avenard

Gilles Avenard

Chief Executive Officer - Chairman of the Board
Andrea Comenducci

Andrea Comenducci

Medical Director
Catherine Boule

Catherine Boule

Eric Cohen

Eric Cohen

Chief Financial Officer
Jean-Pierre Cazenave

Jean-Pierre Cazenave

Independent Director
Leila Nicolas

Leila Nicolas

Show more

Acticor Biotech Office Locations

Acticor Biotech has an office in Paris
Paris, FR (HQ)
46 Rue Henri Huchard
Paris, FR
27 Rue du Faubourg Saint-Jacques
Show all (2)

Acticor Biotech Financials and Metrics

Summary Metrics

Founding Date


Acticor Biotech total Funding

$33.3 m

Acticor Biotech latest funding size

$7.75 m

Time since last funding

a year ago

Acticor Biotech investors

Acticor Biotech's latest funding round in November 2019 was reported to be $7.8 m. In total, Acticor Biotech has raised $33.3 m
Show all financial metrics

Acticor Biotech Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Acticor Biotech Online and Social Media Presence

Embed Graph

Acticor Biotech Blogs

24èmes Journées de la Société Française Neuro-Vasculaire

Retrouvez l'équipe d'Acticor Biotech aux 24èmes Journées de la Société Française Neuro-Vasculaire. 13-15 novembre, 2019, Issy-Les-Moulineaux

Meet us at Bio Europe 2019

Please join us at BioEurope 2019 Congress from November 11th-13th, 2019.


New financing will enable the company to expand in the US its phase II clinical trial ACTIMIS for its drug candidate glenzocimab (ACT017) in acute ischemic stroke Acquisition of 100% of AVCare, a start-up developing a stroke biomarker. Paris, November 6th, 2019 – Acticor Biotech, a clinical stage bi…

Acticor relève 7 millions pour s’attaquer à l’AVC ischémique aigu

  Ce mercredi, Acticor Biotech, dont le candidat médicament phare cible l’AVC ischémique aigu, annonce avoir finalisé un financement secondaire de 7 millions d’euros mené par Go Capital, qui complète son second tour de table à 22,3 millions. En même temps, la société parisienne acquiert la start-up …

Acticor Biotech porte sa série B à 22,3 M€

Novembre 2019. Un an après avoir annoncé un deuxième tour de table de 15,3 M€ pour financer son premier essai clinique de phase II, Acticor Biotech vient de se voir débloquer par ses actionnaires 7 M€ supplémentaires. « Le déclencheur de cette opération est la réponse favorable que nous avons reçue …

7 millions pour s’attaquer à l’AVC ischémique aigu

  Novembre 2019. Ce mercredi, Acticor Biotech annonce avoir levé 7 millions d’euros supplémentaires, qui portent à 22,3 millions son second tour de table, le premier closing datant d’octobre 2018.
Show more

Acticor Biotech Frequently Asked Questions

  • When was Acticor Biotech founded?

    Acticor Biotech was founded in 2013.

  • Who are Acticor Biotech key executives?

    Acticor Biotech's key executives are Gilles Avenard, Andrea Comenducci and Catherine Boule.

  • How many employees does Acticor Biotech have?

    Acticor Biotech has 18 employees.

  • Who are Acticor Biotech competitors?

    Competitors of Acticor Biotech include Ventria Bioscience, Palatin Technologies and Genoa Pharmaceuticals.

  • Where is Acticor Biotech headquarters?

    Acticor Biotech headquarters is located at 46 Rue Henri Huchard, Paris.

  • Where are Acticor Biotech offices?

    Acticor Biotech has an office in Paris.

  • How many offices does Acticor Biotech have?

    Acticor Biotech has 2 offices.